Aliqopa FDA Approval History
FDA Approved: Yes (First approved September 14, 2017)
Brand name: Aliqopa
Generic name: copanlisib
Dosage form: Injection
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Follicular Lymphoma
Aliqopa (copanlisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL).
Development Timeline for Aliqopa
|Sep 14, 2017||Approval FDA Approves Aliqopa (copanlisib) for Adults with Relapsed Follicular Lymphoma|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.